Drug intelligence / Profile preview

SlabON-Hepato

Development stage: Preclinical
Lead developer: Akrocell Biosciences
Modality: Cell Therapies

Overview

SlabON-Hepato is an advanced cell therapy product being developed by Akrocell Biosciences for liver tissue structural regeneration. It utilizes the company's proprietary SlabON® platform, a tissue structure formation technology that integrates biocompatible materials with tissue engineering to create organized, three-dimensional tissue structures. By applying this platform to hepatocytes (liver cells), the therapy aims to facilitate the formation and differentiation of functional liver tissue to treat liver damage or failure. The product is currently in the preclinical stage of development, focusing on regenerative medicine applications for the liver.

Other names: SlabON®-Hepato

Beyond the preview

Go deeper on SlabON-Hepato.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SlabON-Hepato.

Explore the full profile